ClinVar Miner

Submissions for variant NM_017780.4(CHD7):c.7276del (p.Gln2426fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV001195545 SCV001365929 pathogenic CHARGE association 2019-06-05 criteria provided, single submitter clinical testing The p.Gln2426SerfsX17 variant in CHD7 has not been previously reported in individuals with CHARGE syndrome and is absent from large population studies. However, this variant was confirmed to be de novo in an individual with moderate developmental delays, bilateral sensorineural hearing loss, retinal coloboma, scoliosis, and vesicoureteral reflux by the Broad Institute Rare Genomes Project. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 2426 and is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the CHD7 gene is an established disease mechanism in individuals with CHARGE syndrome. In summary, this variant meets criteria to be classified as pathogenic for CHARGE syndrome in an autosomal dominant manner based upon de novo occurrence, its absence from the general population, and its predicted impact on the protein. ACMG/AMP Criteria applied: PVS1, PS2, PM2.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.